National Taiwan University    |    NTU, College of Medicine
NTU, Department of Pharmacy
Graduate Institute of Clinical Pharmacy
Drug Research Center    |     Ching Kang Foundation
Center for Innovative Therapeutics Discovery
Alumni    |    Alumni in North America    |    AASP    |    MRBS
© copyright 2014 SP, NTU. All Rights Reserved.
No.33, Linsen S. Rd., Zhongzheng Dist., Taipei City 100, Taiwan (R.O.C.)
TEL : (02)3366-8750~4    FAX : (02)2391-9098
Web person in charge: Yu-Chen Ho / Tang-Yih Hsu
Contact Phone : (02)33668754 / (02)33668743
Latest Update : 2017 / 08 / 17
Privacy & Security Policy
Wen-Jen Lin
PortfolioPortfolio ResearchResearch
Education:Ph.D. in Pharmaceutics, University of Iowa, USA
Leader of Pharmaceutical Research Group, Drug Research Center
Secretary General, Pharmaceutical Society of Taiwan
Honor:Ching-Kang Foundation Young Teacher award
Professor Li Jhao Ren Foundation Research Scholar award
Research Areas:Nanoparticulate/microparticulate delivery systems, Dosage form design, Pharmacokinetics.
Lab Focus:Our research interest basically focuses on the area of advanced targeting and delivery systems of polymers. We use the modification and synthesis techniques to develop novel polymers with special character and targeting function. Meanwhile, we apply the concept of dosage form design to develop the nanoparticulate/microparticulate delivery systems. The combination of functional polymers and particulate delivery system to achieve targeting and delivery of drug to specific areas of the body is our perspective. The other research interests include the design of micropore-controlled membranes and tablets, and the development of a novel hot-melt fabrication method for microparticles.
Research Subjects:1.Establish a nanoparticle platform for sustained and stomach-specific delivery of acid labile drugs
2.Establish a passive/active targeting nanoparticle/micelle platform for siRNA, pDNA and anticancer drugs delivery
3.Establish a micropore controlled delivery system combined with osmotic driven mechanism to sustain drug release